| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 139, Issue 6 1891-1895, Copyright © 1987 by American Association of Immunologists
ARTICLES |
RM Locksley, FP Heinzel, HM Shepard, J Agosti, TE Eessalu, BB Aggarwal and JM Harlan
The capacity of the tumor necrosis factors, TNF-alpha and TNF-beta, products of activated macrophages and lymphocytes, respectively, to stimulate interleukin 1 (IL-1) release from endothelial cells derived from human umbilical veins was examined in vitro. Recombinant TNF-alpha caused IL-1 release by 4 hr with maximal levels of 17 U/ml by 24 hr; half-maximal stimulation occurred at approximately 80 pM. In contrast, recombinant TNF-beta was a relatively poor stimulus for IL-1 release. Even at concentrations as high as 600 pM, only 3 U of IL-1/ml were recovered; maximal IL-1 release (10 to 12 U/ml) required up to 5 nM TNF- beta. Natural, glycosated human TNF-beta was comparable in activity to recombinant TNF-beta. TNF-beta did not directly inhibit the IL-1 comitogenesis assay, nor was there evidence that TNF-beta induced the release of an IL-1 inhibitor, in that supernatants generated in the presence of TNF-beta did not inhibit thymocyte proliferation to a recombinant IL-1 standard. Binding of the recombinant TNF to endothelial monolayers was assessed by using [125I]TNF-alpha in competition studies with cold TNF-alpha and TNF-beta. Binding of TNF- alpha was half-maximal at 80 pM with an average of 664 receptors/cell and Kd = 0.043 nM. Although TNF-beta was capable of fully competing for [125I]TNF-alpha binding, half-maximal binding occurred at 800 pM TNF- beta. These data suggest that the TNF receptors on human endothelial cells may reflect the structural differences between these two homologous cytokines.
This article has been cited by other articles:
|
|
 |
|
  T. Owaki, A. Meneshian, K. Maemura, S. Takao, D. Wang, K. C. Fuh, G. B. Bulkley, and A. S. Klein Endothelial cells potentiate phagocytic killing by macrophages via platelet-activating factor release Am J Physiol Heart Circ Physiol, January 1, 2000; 278(1): H269 - H276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Taniyama, T. Morita, Y. Yamagishi, A. Kato, C. Bando, N. Okawa, and A. Kaji Human lymphotoxin mutein lacks hypotensive activity but has higher in vivo antitumor activity than lymphotoxin or tumor necrosis factor PNAS, April 1, 1997; 94(7): 3324 - 3329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Medvedev, T. Espevik, G. Ranges, and A. Sundan Distinct Roles of the Two Tumor Necrosis Factor (TNF) Receptors in Modulating TNF and Lymphotoxin alpha Effects J. Biol. Chem., April 19, 1996; 271(16): 9778 - 9784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C.-H. Chen, G. C. DuBois, and M.-J. Chen Mapping the Domain(s) Critical for the Binding of Human Tumor Necrosis Factor-alpha to Its Two Receptors J. Biol. Chem., February 10, 1995; 270(6): 2874 - 2878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Lucas, S Magez, R De Leys, L Fransen, J. Scheerlinck, M Rampelberg, E Sablon, and P De Baetselier Mapping the lectin-like activity of tumor necrosis factor Science, February 11, 1994; 263(5148): 814 - 817. [Abstract] [PDF]
|
|
|
|
|
|
J. Maier, P Voulalas, D Roeder, and T Maciag Extension of the life-span of human endothelial cells by an interleukin-1 alpha antisense oligomer Science, September 28, 1990; 249(4976): 1570 - 1574. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
